Phesi Founder and President Gen Li in a recent interview with Outsourcing-Pharma discussed how the COVID-19 pandemic is affecting clinical trials on a global scale.
The pandemic, Li said, has taken its toll on trial infrastructure, including furloughs and facility closures.
“The virus is rightfully dominating current agendas as the search goes on for a vaccine, but there are other, vital R&D projects — some many years in the making — that must be protected,” Li told Outsourcing-Pharma.
Adopting a more data-driven approach to clinical trials, he said, can help companies “better navigate the challenges ahead and will in fact emerge stronger.”
To read the full discussion on Outsourcing-Pharma, click here.